Sigachi Industries Ltd Q2 FY26 Results & Concall Highlights: Revenue, Margins & Order Book
Published 5 Aug 2026 | Pharmaceuticals & Biotechnology | Market Cap: ₹995 Cr
Sigachi aims for consistent and sustainable growth over the next 2-3 years driven by excipients, APIs, and O&M services. The company aims for consistent and sustainable growth over the next 2-3 years driven by excipients, APIs, and O&M services. - Expansion of capacity, strengthening product mix, and enhancing profitability through operational excellence and disciplined execution are key focus areas. - The additional 12,000 metric tons MCC capacity is expected to generate peak revenue of around Rs.
From Sigachi Industries Ltd's Q2 FY26 earnings-call transcript · updated 23 Aug 2026.
Price
₹30
Market Cap
₹995 Cr
P/E Ratio
30.6
How does Sigachi Industries Ltd rank in Pharmaceuticals & Biotechnology?
Compare Sigachi Industries Ltd against every Pharmaceuticals & Biotechnology company this quarter on revenue, margins and earnings-call signals.
Sigachi Industries Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹117 Cr, net profit ₹0 Cr.
Full financials →📊 Revenue & Sales Performance
- →Sigachi aims for consistent and sustainable growth over the next 2-3 years driven by excipients, APIs, and O&M services. (Page 5)
- →The company expects to achieve not less than Rs.575 crore revenue by FY26 with potential for further increase by March-end. (Page 18)
- →An additional 12,000 metric tons capacity expansion planned, expected to generate around Rs.250 crore in revenue moving forward. (Page 18)
- →FY27 will see partial revenue contributions from the new capacity along with regular growth from existing operations. (Page 18)
- →Despite disruptions, the company expects Q3 and Q4 to stabilize and improve growth momentum. (Page 15, 18)
- →API business revenue contribution is growing, expected to increase gradually alongside MCC and O&M segments. (Page 14)
- →The company is also exploring new plant setups and expansions, such as at Orvakal, pending government approvals. (Page 19)
📈 Profitability & Margins
- →The company aims for consistent and sustainable growth over the next 2-3 years driven by excipients, APIs, and O&M services.
- →Expansion of capacity, strengthening product mix, and enhancing profitability through operational excellence and disciplined execution are key focus areas.
- →The additional 12,000 metric tons MCC capacity is expected to generate peak revenue of around Rs. 250 crores.
- →Margins for CCS facility are expected to be higher than MCC, targeting around 30% EBITDA level.
- →FY26 revenue is expected not to be less than Rs. 575 crores and could increase further by year-end.
- →Growth may face small disturbances in FY26 Q3 and Q4 but expected to stabilize and improve onwards.
- →Debt funding and possible equity infusion will support expansion and working capital needs without guaranteed full utilization of Rs. 1,000 crore debt approval.
- →Overall, disciplined execution and capacity expansion underpin confidence in sustained value creation.
🏗️ Capital Expenditure Plans
- →MCC 12,000 metric tons facility expansion planned with a CAPEX of around Rs.100 crores, expected to generate Rs.250 crores revenue at full capacity. (Page 20)
- →CCS facility requires approximately Rs.60 crores additional CAPEX; Rs.33 crores already available; implementation ongoing. (Page 20)
- →Orvakal facility plans are under consideration (API/MCC), with environmental clearance expected within 30 days; final decisions pending board approval. (Page 19)
- →Minor capital spends planned on safety improvements and process upgrades across existing plants; no significant CAPEX expected for this. (Page 17)
- →Company is strengthening operations and advancing expansion projects aiming to become a fully integrated pharma company. (Page 24)
- →Debt approval sought up to Rs.1,000 crores for future financial flexibility related to CAPEX and working capital, actual debt to be drawn as required. (Page 22 & 16)
💰 Fundraising & Capital Structure
- →The company is seeking shareholder approval for raising debt up to Rs.1,000 crores in the near future, primarily as a borrowing limit for future requirements, not immediate full utilization.
- →Debt drawdowns will be made as needed, with board approval; it may include bank loans or Non-Convertible Debentures (NCDs).
- →The higher debt limit ensures availability of working capital and flexibility to seize opportunities without delay.
- →No direct immediate plans to raise the entire Rs.1,000 crores debt; current working capital limits stand at Rs.200 crores with around Rs.130 crores utilized.
- →Regarding equity fundraising, the company indicated possible plans including preferential share issues but has not disclosed specific details or timing; board approval required prior to any equity infusion.
- →Promoters intend to participate in future fundraisings to increase their stake and reduce pledging.
📋 Order Book & Pipeline
Key Metrics
Frequently Asked Questions
What were Sigachi Industries Ltd Q2 FY26 results?
Sigachi aims for consistent and sustainable growth over the next 2-3 years driven by excipients, APIs, and O&M services. The company aims for consistent and sustainable growth over the next 2-3 years driven by excipients, APIs, and O&M services. - Expansion of capacity, strengthening product mix, and enhancing profitability through operational excellence and disciplined execution are key focus areas. - The additional 12,000 metric tons MCC capacity is expected to generate peak revenue of around Rs.
What is Sigachi Industries Ltd share price analysis?
Sigachi Industries Ltd currently shows a neutral. The stock trades at a P/E of 30.6 with a market cap of ₹995 Cr. Investors should review the full earnings analysis for detailed insights.
Is Sigachi Industries Ltd planning capital expenditure?
MCC 12,000 metric tons facility expansion planned with a CAPEX of around Rs.100 crores, expected to generate Rs.250 crores revenue at full capacity.
Keep Sigachi Industries Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.